Alzheimer disease (AD) is the leading cause of dementia in the elderly. AD occurs at a higher frequency in minority populations, with estimates of AD being twice as frequent in African Americans (AA) compared with non-Hispanic white (NHW) populations.^[@R1],[@R2]^ *APOE* was the first gene associated with AD and the *ε4* allele confers an increased risk across populations.^[@R3],[@R4]^ Although *APOE ε4* occurs more frequently in AA than NHW, paradoxically, it has a lower effect size in AA.^[@R5][@R6][@R7]^ Therefore, while differing ethnicities share risk genes and alleles, the consequences may be different in distinct populations.

Recent studies have identified \>20 additional loci associated with late-onset AD, including *ABCA7*.^[@R8][@R9][@R10]^ Although *ABCA7* was first implicated in NHW, a genome-wide significant signal was also detected in AA individuals at rs115550680, a position in linkage disequilibrium with the NHW genome-wide association study (GWAS) hits.^[@R8],[@R9],[@R11]^ The AA allele confers a higher risk (*p* = 2.21 × 10^−9^, odds ratio \[OR\] = 1.79 \[95% confidence interval (CI): 1.47--2.12\]) than the most significantly associated alleles in NHW.^[@R7][@R8][@R9],[@R11]^ The effect size of the AA *ABCA7* allele is comparable to *APOE ε4* in AA (*p* = 5.5 × 10^−47^, OR = 2.31 \[95% CI: 2.19--2.42\]).^[@R7],[@R11]^ To date, there is no evidence of a functional consequence of the AA *ABCA7* risk allele.^[@R12][@R13][@R15]^ Therefore, targeted sequencing of *ABCA7* was performed to identify potential causative variants. A frameshift deletion was found associated with AD in AA, but was virtually absent in NHW. Thus, this deletion potentially represents a common, ethnic-specific, and likely pathogenic alteration that confers risk to AD.

METHODS {#s1}
=======

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

All the individuals ascertained for this study provided written informed consent prior to their inclusion. If a study participant was not competent to provide consent, the immediate next of kin or a legal representative provided written consent on the behalf of the participant. All participants were ascertained using a protocol that was approved by the appropriate Institutional Review Board. Oversight of this study falls under the University of Miami Institutional Review Board \#20070307.

Sample collection. {#s1-2}
------------------

### African Americans. {#s1-2-1}

Individuals were ascertained for this study after they provided informed consent at the John P. Hussman Institute for Human Genomics (HIHG) at the University of Miami Miller School of Medicine (Miami, FL), North Carolina A&T State University (Greensboro, NC), and Case Western Reserve University (Cleveland, OH) for the HIHG data set. Each of the participants was ascertained using the protocol approved by the proper institutional review boards (IRBs). Patients were collected for this study over the course of 10 years, with IRB protocols and amendments being approved at each stage. For the HIHG cohort (discovery), 539 cases were ascertained (415 women and 124 men, mean age at onset 74.0 years \[SD 8.5\]) and 529 controls (403 women and 126 men, mean age at examination 73.1 years \[SD 5.4\]). The complete HIHG case-control AA cohort (n = 1,068) included 47 relatives, giving 1,021 independent (unrelated) individuals available for analysis.

Samples from the Alzheimer\'s Disease Genetics Consortium (ADGC) were collected as described previously.^[@R11]^ For the ADGC cohort (replication), 687 unrelated cases were ascertained (499 women and 188 men, mean age at onset 78.7 years \[SD 8.5\]) and 1,062 unrelated controls (774 women and 288 men, mean age at examination 78.6 years \[SD 6.7\]). This subset of the ADGC cohort was independent from the HIHG cohort.

For both HIHG and ADGC data sets, participants underwent rigorous phenotyping and diagnostic criteria following those of the National Institute of Neurological and Communicative Disorders and Stroke---Alzheimer\'s Disease and Related Disorders Association, as described previously.^[@R11],[@R15],[@R16]^ Furthermore, the cognitive status of controls was measured with either the Mini-Mental State Examination (MMSE)^[@R17]^ or the Modified Mini-Mental State (3 MS)^[@R18]^ and the Clinical Dementia Rating Scale, which assesses functional decline.^[@R19]^ All the individuals in both cohorts enrolled self-identified as African American. These data were confirmed by analysis of existing GWAS data.^[@R11]^

### Caribbean Hispanics. {#s1-2-2}

Nineteen multiplex Caribbean Hispanic (CH) families initially recruited as a part of the Genetic Epidemiology of Alzheimer\'s Disease In Hispanics family study at Columbia University were included. A total of 49 cases and 8 unaffected relatives were involved in this study. Information about patient recruitment, demographics, and clinical phenotyping has been published previously.^[@R20]^ Each family has at least one member with early-onset AD (age at onset \<65 years old).

Custom capture and whole exome sequencing. {#s1-3}
------------------------------------------

Custom sequence capture was performed on 77 HIHG samples of African American ancestry (40 cases and 37 controls) all with the AA risk allele. Probes were selected using the Agilent SureDesign program across the region (chr19:983277-1133190, ∼150 kb; Agilent Technologies, Santa Clara, CA). Fourteen thousand six hundred thirty-six probes were chosen at a 3× density with the moderately stringent masking setting to cover 84.8% of the region. For whole exome sequencing, samples from the 19 CH families were used (46 cases and 6 unaffected relatives). Capture and sequence library construction was performed on a Sciclone G3 NGS Workstation (Caliper Life Sciences, PerkinElmer, Waltham, MA) using the SureSelect Human All Exon 50 Mb Kit (Agilent Technologies) and the Paired-End Multiplexed Sequencing library kit (Illumina, San Diego, CA) for sequence library preparation. All samples were run on the Illumina HiSeq 2000 and paired-end 2 × 100 sequencing was performed. The sequencing data were processed using the Illumina Real-Time Analysis base calling pipeline version 1.8. The Burrows-Wheeler Aligner was used to map sequences to the hg19 human reference genome, and variant calling was performed with the Genome Analysis Toolkit (GATK^[@R21],[@R22]^). GATK parameters included base quality score recalibration and duplicate removal.^[@R23]^ The data were evaluated for deletions and insertions by alignment with Bowtie2 and analysis using the Pindel program.^[@R24],[@R25]^

Sanger sequencing. {#s1-4}
------------------

Both the *ABCA7* deletion (rs142076058) and the AA *ABCA7* risk allele (rs115550680) were sequenced using traditional Sanger sequencing. Custom primers were designed with the Primer3 v4.0 program (<http://fokker.wi.mit.edu/primer3/input.htm>). For the deletion, primers were selected to flank the 44-base pair (bp) deletion to perform Sanger sequencing for validation (deletion-F: AAATCTTCCCGCCTTGAGAT, deletion-R: GGAGCTTAGGGTGCAGCTC). PCR experiments were set up with 1.5 mM MgCl~2~, 1.6 M betaine, and touchdown PCR was performed. PCR experiments resulted in amplicons of either 450 or 406 bp. Sequencing of the AA risk allele was performed with the following primers (rs115550680-F: GCCAATATGGCAAAACCATC, rs115550680-R: TCCAAAACCCTGTGATAGCC) to generate a 245-bp amplicon. PCR reactions were set up with 2 mM MgCl~2~ and touchdown PCR was performed. Sequencing reactions were performed using the Big Dye Terminator v3.1 (Life Technologies, Carlsbad, CA), reactions were run on a 3730xl DNA Analyzer (Life Technologies), and results were evaluated using the Sequencher v4.10.1 program (Gene Codes Corporation, Ann Arbor, MI).

TaqMan SNP genotyping analysis. {#s1-5}
-------------------------------

Both the *ABCA7* deletion (rs142076058) and the AA *ABCA7* risk allele (rs115550680) were evaluated using the TaqMan single-nucleotide polymorphism (SNP) Genotyping Assays (Life Technologies). The *ABCA7* deletion was evaluated by a custom-designed TaqMan SNP Genotyping Assays designed to recognize the presence or absence of the deletion. This assay had to be ordered as a "non-Human Assay" (forward primer: GCCTGGATCTACTCCGTGAC, reverse primer: GAGGCAGCTGAGGAACCA, FAM probe: GAGACGCGGCTGG---identifies when the sequence is deleted, VIC probe: CGCCATGGGGCT---wild-type allele). Samples were amplified for 40 cycles and, when amplification was low, an additional 20 cycles was added. The plates were read on the 7900HT Fast Real-Time PCR machine (Applied Biosystems, Foster City, CA), and data were analyzed with the SDS v2.4 software.

RNA isolation and real-time PCR. {#s1-6}
--------------------------------

RNA was isolated from blood collected in PAXgene blood RNA tubes (PreAnalytiX, Hombrechtikon, Switzerland) from 10 samples with and 10 samples without the *ABCA7* deletion and extracted following the manufacturer\'s standard protocol. RNA was quantified on the 2100 BioAnalyzer (Agilent Technologies) and was required to have an RIN ≥6. Complementary DNA (cDNA) libraries were generated using the iScript Reverse Transcriptase Supermix for RT-qPCR kit (BIO-RAD). PCR primers were designed to amplify the cDNA across the deletion (cDNA-F: TGTTCCTGCGTGTGCTGA, cDNA-R: AGCAGGAAGCTCTGGGTCAC) and the resulting PCR products resolved on a 2% agarose gel. The wild-type allele results in an amplicon of 316 bp, whereas the allele with the deletion produces a 272-bp amplicon.

Statistical analysis. {#s1-7}
---------------------

The GENMOD program, as part of the SAS/STAT software, was used to perform the association tests under a logistic regression model. Association tests were performed with adjustments for age, sex, *APOE* status, and relatedness between samples (SAS Institute, Cary, NC). Conditional analysis was performed in PLINK.^[@R26]^ The Fisher exact test was used to evaluate the differences in the alleles frequency of the deletion between African and European populations reported in the ExAC database.

RESULTS {#s2}
=======

We selected 40 AA AD cases and 37 AA controls (aged \>65 years) carrying the AA risk allele, rs115550680, to perform custom massively parallel sequencing of a ∼150-kb region that includes *ABCA7* and 8 flanking genes and a small nuclear RNA. Samples were sequenced to an average depth of over 1,000× and evaluated for single-nucleotide variants (SNVs) and insertions and deletions. One thousand one hundred twenty SNVs were detected by sequencing with 11 variants showing different frequencies in cases and controls (*p* \< 0.1, table e-1 at [Neurology.org/ng](10.1212/NXG.0000000000000079)). In addition, a 44-base pair (bp) deletion (rs142076058, p.Arg578Alafs) located ∼3.5 kb upstream of the AA risk allele was identified in all 77 individuals, which suggests that it is in high linkage disequilibrium with the risk allele ([figure 1](#F1){ref-type="fig"}).

![Location of the deletion in the *ABCA7* gene and protein\
(A) *ABCA7* gene (chr19:1,040,103-1,065,571, hg38), 44-base pair deletion (blue), African American risk allele (blue and underlined^[@R11]^), and 3 non-Hispanic white (NHW) risk alleles (rs3764650,^[@R8]^ rs3752246,^[@R9]^ and rs4147929^[@R10]^). (B) Wild-type ABCA7 protein (2,146 amino acids) and the location of frameshift deletion (blue) identified in this study. Below, the protein predicted to be generated from deletion would contain only 2 of the 11 transmembrane domains (yellow) and neither of the 2 AAA domains (green), but incorporate 168 aberrant amino acids (black). The remaining frameshift, nonsense, and splicing variants designated are rare alterations (\<1% minor allele frequency) previously reported in NHW populations to be associated with Alzheimer disease.^[@R33][@R34][@R35]^](NG2016001859FF1){#F1}

To further evaluate the rs142076058 deletion, a custom TaqMan genotyping assay was designed to evaluate the deletion in our larger AA cohort, designated as HIHG. After adjustments for age, sex, and *APOE* status, the deletion was found to be significantly associated with AD (*p* = 0.0002, OR = 2.13 \[95% CI: 1.42--3.20\], [table 1](#T1){ref-type="table"}) in 531 cases and 527 controls. The deletion occurred in 9.3% of control individuals but in 16.2% of AD cases. A subset of 8 individuals were pathologically confirmed cases of AD; 2 were found to carry the deletion whereas the remaining 6 did not. The AA risk allele was also genotyped in this data set. The risk allele was significantly associated with AD (*p* = 0.0005, OR = 2.07 \[95% CI: 1.38--3.13\]) and in linkage disequilibrium with the deletion (D′ = 1.000, *r*^2^ = 0.995, tables e-2 and e-3). The top SNPs in *ABCA7* reported previously in NHW studies were also found to be in linkage disequilibrium with the deletion (table e-4).^[@R8],[@R9],[@R11]^ Genotyping was also performed on our NHW AD samples (n = 3,275), but only 4 individuals were identified with the deletion (0.12%), all of whom carried the AA risk allele, which indicates that the genomic fragment carrying the deletion in these individuals may be of African descent.

###### 

Association testing of the deletion in African American cohorts

![](NG2016001859TT1)

An independent AA data set from the Alzheimer\'s Disease Genetics Consortium (ADGC) was evaluated in the same manner, and the deletion was again associated with AD (*p* = 0.0117, OR = 1.65 \[95% CI: 1.12--2.44\], [table 1](#T1){ref-type="table"}), occurring in 10.0% of control individuals and 14.9% of AD cases. Joint analysis of the 2 cohorts increased the strength of the association (*p* = 1.414 × 10^−5^, OR = 1.81 \[95% CI: 1.38--2.37\], [table 1](#T1){ref-type="table"}). Association testing was also performed for each data set without *APOE* adjustment; more significant results were obtained with *APOE* adjustment, demonstrating that *APOE* did not influence the association (table e-5). Examination of the ages of cases and controls with and without the deletion did not find a significant difference between any of these groups (table e-6).

To examine the association with AD in another ethnic group with a high level of African ancestry (∼42%), we evaluated whole exome sequencing data on 19 CH families from the Dominican Republic with multiple affected AD participants.^[@R27]^ In addition to a relatively high level of African ancestry, CHs are highly inbred and have a high incidence of AD, and are thus enriched for AD genetic risk factors.^[@R28]^ We independently identified the same 44-bp deletion from whole exome sequencing of 3 affected individuals from a large CH family. Subsequent examination of the family revealed that the deletion segregated in a large sibship in the family ([figure 2](#F2){ref-type="fig"}). Both the deletion and AA risk allele were isolated in all 7 siblings who clinically presented in a range from AD (individuals 5, 6, 8, 12, and 99) to milder stages of dementia (individuals 7 and 11). Haplotype analysis around the *ABCA7* deletion using SNP data in the 1-Mb flanking region on the family revealed that an affected aunt who does not carry the deletion, individual 3 ([figure 2](#F2){ref-type="fig"}), has distinct ancestral haplotypes from the family members in the large sibship with the deletion (table e-7). This finding suggests that individual 3\'s AD phenotype can be attributed to other genetic factors and that the *ABCA7* deletion is highly penetrant in the sibship. Because several members of this CH family were known to have early-onset AD (age at onset \<65 years), we examined the entire AA AD cohort (both HIHG and ADGC) to determine whether there was an effect of the deletion on age at onset in AD. We found no difference in the age at onset in cases with the deletion (75.6 years \[SD 9.6\]) compared with cases absent for the deletion (76.8 years \[SD 8.7\], *p* = 0.09).

![Pedigree of an AD family from the Dominican Republic with the *ABCA7* deletion\
Family 360 has 6 individuals diagnosed with Alzheimer disease (AD) and 2 individuals presenting with mild dementia. The numbers beneath each individual in the pedigree represent the individual\'s sample number, the age at onset of AD (for AD cases) or the age at examination, and the *APOE* genotype. All 7 siblings carry the *ABCA7* deletion and the African Americans (AA) risk allele, whereas individual 3 had neither the deletion nor the AA risk allele.](NG2016001859FF2){#F2}

To determine whether the *ABCA7* allele with the deletion was being transcribed, RNA was isolated from the blood of AA individuals both with and without the *ABCA7* deletion. Reverse transcription PCR across the deletion region demonstrated that the allele carrying the deletion is transcribed and produces a stable detectable RNA strand ([figure 3](#F3){ref-type="fig"}).

![Deletion allele produces an RNA transcript\
(A) Real-time PCR from cDNA of 3 samples without the *ABCA7* deletion (+/+) and 3 samples heterozygous for the *ABCA7* deletion (deletion/+). All samples produce an amplicon of 316 base pairs, but only the samples with deletion generate a lower, 272-base pair amplicon (arrow). (B) Sanger sequencing from the 5′ end of the deletion in an African American control lacking the deletion and Alzheimer disease (AD)-specific line heterozygous for the deletion. The arrow denotes where the deleted allele begins to be out of frame with the wild-type allele C. Sanger sequencing from the 3′ end of the deletion from the same control and AD individuals.](NG2016001859FF3){#F3}

This deletion was reported previously in the Exome Aggregation Consortium (ExAC: <http://exac.broadinstitute.org>) \[June 2015\], a repository of 60,706 unrelated individuals from 6 distinct ethnic groups. In the ExAC data set, the deletion was found in 7.77% of individuals of African ancestry and 0.95% of Latino individuals, but was absent from individuals of European ancestry. This difference in population frequencies between the African and European populations was highly significant (*p* \< 1 × 10^−10^).

DISCUSSION {#s3}
==========

We identified a 44-bp deletion in *ABCA7* that is associated with AD in individuals of African ancestry. Although the deletion did occur in unaffected individuals, it was found at a higher frequency in individuals with AD (15.2% of cases vs 9.74% of controls), implicating it as a risk factor for disease. This reaffirms that the deletion is likely to be of African ancestry. Furthermore, the combined cases from the HIHG and ADGC data sets had the deletion at a frequency of 15.2%, approximately twice as high as that identified with through ExAC African populations (7.8%), lending additional evidence of a relationship to disease. The deletion was also independently identified in an AD family from the Dominican Republic, a population that has a relatively high level of African ancestry, 41.8%.^[@R27]^ Examination of the linkage disequilibrium of the deletion with the top 3 previously reported SNPs found a high D′ across all locations, but only a large *r*^2^ with the African-specific risk allele (table e-4), further supporting that distinct alleles confer AD risk in different ethnicities.^[@R8],[@R9],[@R11]^

The deletion is predicted to cause a frameshift at amino acid 578, encoding for 168 incorrect amino acids before stopping prematurely compared with the largest isoform that generates a protein of 2,146 amino acids ([figure 1B](#F1){ref-type="fig"}). Because we were able to detect RNA from the allele with the deletion, it is possible that this RNA generates an aberrant protein that interferes with the wild-type 2,146 amino acid protein. Within the first 578 amino acids, 2 transmembrane regions are conserved and would be maintained by the mutated protein ([figure 1B](#F1){ref-type="fig"}). However, both AAA domains and 9 additional transmembrane domains would be predicted to be lost in this truncated protein, and thereby interfere with the protein\'s function of exporting the lipid phosphatidylserine.^[@R29]^ Alternatively, the shortened transcript may be subjected to nonsense-mediated decay (NMD), as was seen in the Glu709fs alteration identified in NHW.^[@R30]^ Although some loss-of-function variants in *ABCA7* were identified in NHW populations that may contribute to AD pathogenicity, these are rare variants and may only partially contribute to the NHW GWAS signal.^[@R30][@R31][@R32]^ A few previously reported loss-of-function variants have demonstrated a functional consequence including the Glu709fs variant undergoing NMD, and the c.5570+5G\>C alteration led to aberrant splicing^[@R30],[@R31]^ ([figure 1B](#F1){ref-type="fig"}). Therefore, this study may be the first to connect a potentially pathogenic and common alteration with a GWAS signal in *ABCA7*.

*ABCA7* is a member of the ATP-binding cassette (ABC) transporter family, a large group of 49 genes that encode for membrane proteins that facilitate the movement of substrates across cell membranes.^[@R33],[@R34]^ *ABCA7* is expressed in the brain in neurons and microglia.^[@R35],[@R36]^ There is evidence both in patients and animal models demonstrating that inadequate levels of *ABCA7* may be directly correlated with Alzheimer pathogenesis.^[@R37][@R38][@R39]^ The ABCA7 protein is involved in the processing of amyloid precursor protein.^[@R40]^ In addition, evidence has shown that ABCA7 acts in the phagocytic pathway through extracellular signal-regulated kinase signaling.^e1,e2^ *ABCA7* is not the only ABC transporter gene linked to AD; *ABCA1*, *ABCB1*, *ABCC1*, *ABCG1*, *ABCG2*, and *ABCG4* are all implicated in Aβ regulation.^e3--e8^ Furthermore, a study identified rare loss-of-function alterations in NHW patients diagnosed with Parkinson disease, including specific variants previously reported in AD individuals, which demonstrates that this gene may contribute to the risk of multiple neurodegenerative disorders.^e9^

Therefore, the results of this study demonstrate that there is a 44-bp deletion in *ABCA7* that is associated with AD and in linkage disequilibrium with the previously identified AA risk allele. The deletion was relatively frequent in our large AA AD cohorts, independently identified in 1 of 19 CH AD families, and virtually absent from our large NHW AD cohort. Thus, the deletion could represent a common, ethnic-specific alteration that confers risk of AD in populations with African ancestry.
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